That graph looks pretty much what I’d expect from a biotech company plodding through early-stage clinical trials reflecting a nice steady burn of shareholder funds with enough good news spikes to keep us all engaged.
Oh and surprise surprise you haven’t shown the little upward movement of the last few days.
What’s your point* ?
Maybe you can compare/contrast with another bio stock in the four years PRIOR to a ‘breakthrough’ event like a Phase III start?
No?
Thought not.
* some would phrase that … ‘What’s the point of you?’. Not me.
Ann: First Australian Patient Dosed in Phase 1b azer-cel Trial, page-130
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |